Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Rodríguez, Mariano ^a   Aguilera Tejero, Escolástico ^b   Mendoza, F Javier ^b   Guerrero, Fátima ^b   López, Ignacio ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Calcimimetic; Extraosseous calcification; Hyperparathyroidism; Vascular calcification; Vitamin D

Indexed keywords

AMG 641; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ION; CALCIUM SENSING RECEPTOR; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; R 568; UNCLASSIFIED DRUG;

BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; MORBIDITY; MORTALITY; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SECONDARY HYPERPARATHYROIDISM; UREMIA; ANIMAL; CALCINOSIS; CHRONIC DISEASE; DISEASE MODEL; DRUG POTENTIATION; HYPERPARATHYROIDISM; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW; VASCULAR DISEASE;

ANIMALS; CALCINOSIS; CALCIUM; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; HYPERPARATHYROIDISM; KIDNEY DISEASES; RATS; VASCULAR DISEASES;

EID: 61549092494     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.546     Document Type: Conference Paper

References (49)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
3. Proudfoot D, Shanahan CM. Biology of vascular calcification in vascular cells: intima versus media. Herz 2001; 26: 245-251.
4. Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol 2000; 89: 101-104.
5. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695.
6. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004; 33: 183-189.
7. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
8. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
9. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 2005; 16: 1788-1793.
10. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
11. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
12. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567.
13. Giachelli CM, Jono S, Shioi A et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38: S34-S37.
14. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14(Suppl 4): S300-S304.
15. Amann K, Tornig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301.
16. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964.
17. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299.
18. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
19. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
20. Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian group for the study of intravenous calcitriol. Kidney Int 1992; 42: 1191-1198.
21. Tan Jr AU, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323.
22. McCullough PA, Sandberg KR, Dumler F et al. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004; 17: 205-215.
23. Merke J, Hoffmann W, Goldschmidt D et al. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 1987; 41: 112-114.
24. Inoue T, Kawashima H. 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun 1988; 152: 1388-1394.
25. Jono S, Nishizawa Y, Shioi A et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998; 98: 1302-1306.
26. Bas A, Lopez I, Perez J et al. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006; 21: 484-490.
27. Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I et al. Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res 1997; 34: 386-398.
28. Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
29. Levi R, Ben-Dov IZ, Lavi-Moshayoff V et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor Auf1. J Am Soc Nephrol 2006; 17: 107-112.
30. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627-635.
31. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
32. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807.
33. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroidhormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024.
34. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583.
35. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254.
36. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804.
37. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
38. Farzaneh-Far A, Proudfoot D, Weissberg PL et al. Matrix Gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000; 277: 736-740.
39. Molostvov G, James S, Fletcher S et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007; 293: 946-955.
40. Murshed M, Schinke T, McKee MD et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625-630.
41. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997; 386: 78-81.
42. Shiraishi N, Kitamura K, Miyoshi T et al. Succesful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidrionate disodium. Am J Kidney Dis 2006; 48: 151-154.
43. Cicone JS, Petronis JB, Embert CD et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108.
44. Meissner M, Bauer R, Beier C et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006; 212: 373-376.
45. Brucculeri M, Cheigh J, Bauer G et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005; 18: 431-434.
46. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplantation 2005; 20: 1260-1262.
47. Mataic D, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail 2006; 28: 361-363.
48. Velasco N, MacGregor MS, Innes A et al. Succesful treatment of calciphylaxis with cinacalcet - an alternative to parathyroidectomy? Nephrol Dial Transplantation 2006; 21: 1999-2004.
49. Zerbi S, Ruggiero P, Pedrini LA. Massive soft tissue calcifications andcinacalcet. J Clin Endocrinol Metab 2008; 93: 1121-1122.